Overview
Investment fund focused on developing critical pathogen therapies.
Founded
2020
Deals · 12mo
4
Stage focus
Geographic focus
Sector focus
Investment portfolio
| NAME | DATE | SIZE | |
|---|---|---|---|
Vedanta Biosciences | Aug 2026Led | $40 MOther Equity | |
Trellis Bioscience | Jul 2026Participated | $9 MSeries C | |
Telum Therapeutics | Jul 2026Led | $21 MSeries A | |
Centauri Therapeutics | Feb 2026Led | $8 MSeries A | |
Peptilogics | Oct 2025Participated | $78 MSeries B | |
TenNor Therapeutics | Oct 2024Participated | $42 MSeries E | |
F2G | Sep 2024Led | $100 MOther Equity | |
Elion Therapeutics | Jun 2024Led | $81 MSeries B | |
Antabio | Dec 2023Participated | $27 MSeries B | |
Adaptive Phage Therapeutics | Jun 2023Led | $24 MSeries B | |
Pattern Bioscience | Apr 2023Participated | $29 MSeries C | |
Vedanta Biosciences | Apr 2023Led | $107 MOther Equity | |
Vedanta Biosciences | Aug 2026Led | $40 MOther Equity | |
Trellis Bioscience | Jul 2026Participated | $9 MSeries C | |
Telum Therapeutics | Jul 2026Led | $21 MSeries A | |
Centauri Therapeutics | Feb 2026Led | $8 MSeries A | |
Peptilogics | Oct 2025Participated | $78 MSeries B | |
TenNor Therapeutics | Oct 2024Participated | $42 MSeries E | |
F2G | Sep 2024Led | $100 MOther Equity | |
Elion Therapeutics | Jun 2024Led | $81 MSeries B | |
Antabio | Dec 2023Participated | $27 MSeries B | |
Adaptive Phage Therapeutics | Jun 2023Led | $24 MSeries B | |
Pattern Bioscience | Apr 2023Participated | $29 MSeries C | |
Vedanta Biosciences | Apr 2023Led | $107 MOther Equity |
Insights
Time horizon
View by
Deal Distribution
| Round type | Led deals | Participated deals |
|---|---|---|
| Series A | 2 | 0 |
| Series B | 2 | 3 |
| Series C+ | 1 | 3 |
| Other Equity | 3 | 0 |
Monthly Deal Activity
| Month | Deals |
|---|---|
| Apr '22 | 1 |
| May '22 | 0 |
| Jun '22 | 0 |
| Jul '22 | 0 |
| Aug '22 | 0 |
| Sep '22 | 0 |
| Oct '22 | 0 |
| Nov '22 | 0 |
| Dec '22 | 0 |
| Jan '23 | 1 |
| Feb '23 | 0 |
| Mar '23 | 0 |
| Apr '23 | 2 |
| May '23 | 0 |
| Jun '23 | 1 |
| Jul '23 | 0 |
| Aug '23 | 0 |
| Sep '23 | 0 |
| Oct '23 | 0 |
| Nov '23 | 0 |
| Dec '23 | 1 |
| Jan '24 | 0 |
| Feb '24 | 0 |
| Mar '24 | 0 |
| Apr '24 | 0 |
| May '24 | 0 |
| Jun '24 | 1 |
| Jul '24 | 0 |
| Aug '24 | 0 |
| Sep '24 | 1 |
| Oct '24 | 1 |
| Nov '24 | 0 |
| Dec '24 | 0 |
| Jan '25 | 0 |
| Feb '25 | 0 |
| Mar '25 | 0 |
| Apr '25 | 0 |
| May '25 | 0 |
| Jun '25 | 0 |
| Jul '25 | 0 |
| Aug '25 | 0 |
| Sep '25 | 0 |
| Oct '25 | 1 |
| Nov '25 | 0 |
| Dec '25 | 0 |
| Jan '26 | 0 |
| Feb '26 | 1 |
| Mar '26 | 0 |
| Apr '26 | 0 |
| May '26 | 0 |
| Jun '26 | 0 |
| Jul '26 | 2 |
| Aug '26 | 1 |
| Sep '26 | 0 |
| Oct '26 | 0 |
Sector Breakdown
A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.
| Sector | Deals |
|---|---|
| Health & Life Sciences | 14 |
| Professional Services | 2 |
Deal Size Distribution
Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.
| Round size band (USD) | Deals |
|---|---|
| <$5M | 0 |
| $5M-$10M | 2 |
| $10M-$25M | 3 |
| $25M-$50M | 5 |
| $50M-$100M | 2 |
| $100M-$250M | 2 |
| $250M-$500M | 0 |
| $500M-$1B | 0 |
| $1B+ | 0 |
Deals By Geography
Top 2 of 2 regions; European countries are grouped as Europe.
| Region | Deals |
|---|---|
| United States | 9 |
| Europe | 5 |
Co-Investors
Bubble size = shared deals
Click a bubble to open that fund in a new tab.
Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.
| Co-investor | Shared deals |
|---|---|
| Deerfield Management | 3 |
| Advent Life Sciences | 1 |
| Atlantic Neptune | 1 |
| AXA IM Alts | 1 |
| Beyond Ventures | 1 |
| Bill & Melinda Gates Foundation | 1 |
| BNP Capital | 1 |
| BNP Paribas Développement | 1 |
| Brace Pharma Capital | 1 |
| CDTI | 1 |
| Clave Capital | 1 |
| Daleshaw | 1 |
| Easton Capital | 1 |
| EIC Fund | 1 |
| Fiscus Ventures | 1 |
| Forbion | 1 |
| Founders Fund | 1 |
| Illinois Ventures | 1 |
| Illumina Ventures | 1 |
| Intermediate Capital Group | 1 |
Investment Strategy
| Category | Deals (count) | Share (%) |
|---|---|---|
| Led | 8 | 57% |
| Participating | 6 | 43% |
| Category | Deals (count) | Share (%) |
|---|---|---|
| Single-lead | 4 | 50% |
| Co-led | 4 | 50% |
Team
Chief Executive Officer
Managing Director